Brief: OSE Immunotherapeutics Receives European Patent Notice Of Allowance For First-In-Class CD28-Antagonist Immunotherapy FR104

Ose Immunotherapeutics SA

12/10/2020 18:45

Oct 12 (Reuters) - Ose Immunotherapeutics SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS RECEIVES EUROPEAN PATENT NOTICE OF
ALLOWANCE FOR FIRST-IN-CLASS CD28-ANTAGONIST IMMUNOTHERAPY FR104
    * OSE IMMUNOTHERAPEUTICS SA - RESULTS FROM FR104'S PHASE 1
CLINICAL STUDY HAVE SHOWN INITIAL SIGNALS OF EFFICACY

Source text for Eikon:  ID:nGNX9TpFHF 
Further company coverage:  OSE.PA 

 ((Reuters.briefs@thomsonreuters.com;))